Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • New AstraZeneca, Amgen ...

    New AstraZeneca, Amgen drug looks strong rival in severe asthma

    By Ruby Khatun KhatunPublished On 2017-09-11T10:27:55+05:30  |  Updated On 2021-08-18T15:23:44+05:30

    LONDON: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines like GlaxoSmithKline's Nucala.


    Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the experimental drug tezepelumab reduced the annual rate of serious asthma attacks, known as exacerbations, by between 61 and 71 percent, depending on dose.


    The results could put the first-in-class injection in a strong position in a competitive market as it heads into final-stage Phase III tests later this year or early next.


    "Tezepelumab appears to be the broadest and most promising biologic for the treatment of persistent uncontrolled asthma to date," Elisabeth Bel of Amsterdam's Academic Medical Center wrote in an editorial in the New England Journal of Medicine.


    Still, she cautioned researchers needed to confirm its safety profile in larger trials, since there was a potential risk its impact on the immune system might lead to infections.


    Shares in AstraZeneca rose 1 percent on Thursday following the news, with Barclays analysts citing it as an example of the strength of the drugs pipeline beyond cancer, which will be in focus at a medical meeting in Madrid this weekend.


    Injections for severe asthma have opened up a multi-billion-dollar market as competing drug makers have raced to develop antibody-based medicines for the 15 percent or more of patients who do poorly even on the latest inhalers.


    Despite treatment advances in recent decades, their asthma is still not well controlled by standard therapy, which consists of inhaled steroids and drugs to open the airways.


    Nucala and Teva's Cinqair are two recently approved new injectable drugs and AstraZeneca's benralizumab is likely to join them soon since it is awaiting approval in the fourth quarter of this year.


    Sanofi's Dupixent, already approved for severe eczema, is a bit further behind but is widely seen as a strong contender.


    However, all these new medicines only appear to help people with certain types of severe asthma, by targeting specific inflammatory chemicals made in the body that drives asthma, making them suitable for subgroups of patients.


    Tezepelumab is different because it acts further upstream in the inflammatory cascade responsible for asthma by blocking the action of a cell-signaling protein called thymic stromal lymphopoietin (TSLP).


    That means it can help a wider range of patients and could be a "game-changer", according to Tom Keith-Roach, head of AstraZeneca's respiratory, inflammation and autoimmune business.


    Biotech drugs for severe asthma are already worth $2 billion in annual sales and Keith-Roach believes there is significant scope for growth since currently, only about 10 percent of patients who might benefit are getting them.


    Tezepelumab, like Dupixent, is also being developed for eczema.


    The results of the Phase IIb asthma study, which were published online by the New England Journal of Medicine, will also be presented at the European Respiratory Society annual meeting in Milan next week.




    (Reporting by Ben Hirschler; Editing by Mark Potter)



    Amgen asthma AstraZeneca benralizumab biotech Cinqair drug Dupixent eczema European Respiratory Society GlaxoSmithKline injectable New England Journal of Medicine Nucala Sanofi severe asthma strong rival Teva tezepelumab thymic stromal lymphopoietin 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X